The growing prevalence of prediabetes among children and adolescents suggests that unhealthy, inactive lifestyles are increasing in the US.

World Brain Day draws attention to the increasing prevalence of Alzheimer's and PD in an ageing global population.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.

Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings.

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.